Metformin‐based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population‐based study
Newly diagnosed type 2 diabetes mellitus (T2DM) patients using metformin (MET)-glinides and MET-sulfonylureas are at an increased risk of dementia. The MET-glinides group had the highest risk of dementia. The MET-dipeptidyl peptidase-4 inhibitor group had the lowest risk of dementia, followed by the MET-thiazolidinedione group.
Authors
- Wei‐Chuan Chang (ORCID: https://orcid.org/0009-0009-8781-9708)
- Tsung‐Cheng Hsieh (ORCID: https://orcid.org/0000-0003-3024-8675)
- Hung‐Chun Chen (ORCID: https://orcid.org/0000-0002-5808-9920)
- C.L. Ho (ORCID: https://orcid.org/0000-0001-5580-7846)
Institutions
- Tzu Chi College of Technology (TW)
- Tzu Chi University (TW)
- Tzu Chi Foundation (TW)
- Hualien Tzu Chi Medical Center (TW)
- Buddhist Tzu Chi Medical Foundation (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/alz.70590
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29